A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-Refractory prostate cancer

Yoo Joung Ko, Eric J. Small, Fairooz Kabbinavar, Abraham Chachoua, Samir Taneja, David Reese, Ann Depaoli, Alison Hannah, Steven P. Balk, Glenn J. Bubley

    Research output: Contribution to journalArticlepeer-review

    Fingerprint Dive into the research topics of 'A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-Refractory prostate cancer'. Together they form a unique fingerprint.

    Medicine & Life Sciences